1. Cellular senescence in age-related disorders
- Author
-
Japneet Kaur and Joshua N. Farr
- Subjects
0301 basic medicine ,Senescence ,Aging ,ved/biology.organism_classification_rank.species ,Population ,Bioinformatics ,Article ,Proinflammatory cytokine ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,Pulmonary fibrosis ,medicine ,Animals ,Humans ,Model organism ,education ,Cellular Senescence ,education.field_of_study ,Geroscience ,ved/biology ,Mechanism (biology) ,business.industry ,Biochemistry (medical) ,Public Health, Environmental and Occupational Health ,General Medicine ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Steatosis ,business - Abstract
Much of the population is now faced with an enormous burden of age-associated chronic diseases. Recent discoveries in geroscience indicate that healthspan in model organisms such as mice can be manipulated by targeting cellular senescence, a hallmark mechanism of aging, defined as an irreversible proliferative arrest that occurs when cells experience oncogenic or other diverse forms of damage. Senescent cells and their pro-inflammatory secretome have emerged as contributors to age-related tissue dysfunction and morbidity. Cellular senescence has causal roles in mediating osteoporosis, frailty, cardiovascular diseases, osteoarthritis, pulmonary fibrosis, renal diseases, neurodegenerative diseases, hepatic steatosis, and metabolic dysfunction. Therapeutically targeting senescent cells in mice can prevent, delay, or alleviate each of these conditions. Therefore, senotherapeutic approaches, including senolytics and senomorphics, that either selectively eliminate senescent cells or interfere with their ability to promote tissue dysfunction, are gaining momentum as potential realistic strategies to abrogate human senescence to thereby compress morbidity and extend healthspan.
- Published
- 2020